Bruker Reports Second Quarter 2026 Financial Results

BRUKER CORP (BRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bruker Reports Second Quarter 2026 Financial Results • Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x • Q2-26 revenue of $838.5 million, up +5.2% yoy; up 2.8% organically, or +3.4% excluding tar

Event · Guidance
Original reporting
Published Aug 4, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 11:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BRKR
Bullish
medium confidence
Mentioned
$BRKR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BRKRBullishMed
01

Why it matters

Traders can update models using the new Q2 datapoints and the revised FY2026 revenue and non-GAAP EPS ranges, while noting management’s guidance change is limited to currency and tax.

02

Market read

The filing provides fresh quarterly performance and a specific FY2026 non-GAAP EPS range ($2.10 to $2.15), supporting near-term positioning in BRKR.

03

What to watch

GAAP results include $134.9M non-cash goodwill impairment charges, which can keep longer-term risk perception elevated even if non-GAAP profitability improves.

Relevance 7/10Novelty 8/10Timing: pre-market today (SEC 8-K filed Aug 4, 2026)
AlphAI · Earnings readBRKR · Q2-26 · ended June 30, 2026

Q2-26 revenue of $838.5 million, up +5.2% yoy; GAAP diluted loss per share of $(0.41) and non-GAAP diluted EPS of $0.49.

→Mixed quarter

Revenue returned to organic growth and non-GAAP operating income, margin and EPS improved, but GAAP results were affected by $134.9 million of non-cash goodwill impairment charges and US academic demand remained soft.

Revenue
$839M
5.2% y/y
Bruker Scientific Instruments (BSI), Q2-26
$767M
4.7% y/y
Operating margin · non-GAAP
14.1%
EPS · non-GAAP
$0.49
FY26 outlook
$3.54 to $3.57 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, Q2-26GAAP$838.5M–5.2%
Organic revenue growth, Q2-26other2.8%––
Organic revenue growth excluding tariff refunds, Q2-26other3.4%––
Growth from acquisitions, Q2-26other1.5%––
Constant-exchange rate revenue growth, Q2-26other4.3%––
Foreign currency translation impact, Q2-26other0.9%––
GAAP operating loss, Q2-26GAAP−$65.3M––
Non-GAAP operating income, Q2-26non-GAAP$118.5M––
Non-GAAP operating margin, Q2-26non-GAAP14.1%––
GAAP diluted loss per share, Q2-26GAAP$(0.41)––
Non-GAAP diluted EPS, Q2-26non-GAAP$0.49––
Total revenue, first half of 2026GAAP$1.7B–3.9%
Organic revenue growth, first half of 2026other(0.8%)––
Growth from acquisitions, first half of 2026other2.0%––
Constant-exchange rate revenue growth, first half of 2026other1.2%––
Foreign currency translation impact, first half of 2026other2.7%––
GAAP operating loss, first half of 2026GAAP−$55.1M––
Non-GAAP operating income, first half of 2026non-GAAP$202.7M––
Non-GAAP operating margin, first half of 2026non-GAAP12.2%––
GAAP diluted loss per share, first half of 2026GAAP$(0.39)––
Non-GAAP diluted EPS, first half of 2026non-GAAP$0.80––
Non-cash goodwill impairment charges, Q2-26GAAP$134.9M––

Segments

SegmentRevenueq/qy/y
Bruker Scientific Instruments (BSI), Q2-26Organic revenue increased by 2.3%; bookings were up 10% organically year-over-year and book-to-bill was >1.0x.$767.3M–4.7%
Bruker Energy & Supercon Technologies (BEST), Q2-26Organic revenue increased by 8.9%, net of intercompany eliminations.$74.2M–11.9%
Bruker Scientific Instruments (BSI), first half of 2026Revenue decreased by 1.4% organically.$1.5B–3.3%
Bruker Energy & Supercon Technologies (BEST), first half of 2026Organic growth was 6.1%, net of intercompany eliminations.$141M–12.3%

FY26 outlook

  • Revenue$3.54 to $3.57 billion
  • Tax rate27.5%
  • Note3% to 4% year-over-year reported revenue growth
  • NoteOrganic revenue growth of 1% to 2%
  • NoteM&A revenue growth of approximately 1.5%
  • NoteCER revenue growth of 2.5% to 3.5%
  • NoteForeign currency translation revenue tailwind of approximately 0.5% (previously 1.5%)
  • NoteNon-GAAP EPS of $2.10 to $2.15
  • NoteNon-GAAP EPS growth of 15% to 17% year-over-year
  • NoteCurrency headwind of approximately $0.10, or 5%

What drove it

  • Q2-26 BSI bookings were up 10% organically year-over-year, with BSI book-to-bill >1.0x.
  • Bruker cited strong order bookings growth for differentiated products and solutions in semiconductor tools, energy research and biopharma markets.
  • Europe and China aca/gov bookings were up strongly.
  • Q2-26 reported revenue growth included 1.5% growth from acquisitions and a favorable 0.9% foreign currency translation impact.
  • Management cited a focus on cost and profitability and reported non-GAAP operating-margin expansion.

Concerns

  • US academic demand remained soft in Q2.
  • First-half revenue decreased organically by 0.8% year-over-year.
  • Q2-26 GAAP operating loss included non-cash goodwill impairment charges of $134.9 million.
  • FY26 foreign currency translation revenue tailwind is approximately 0.5%, previously 1.5%.
  • FY26 non-GAAP EPS includes a currency headwind of approximately $0.10, or 5%.

What to watch

  • Whether BSI bookings growth and book-to-bill >1.0x translate into sustained revenue growth.
  • The trajectory of US academic demand and the stated gradual market recovery.
  • Execution toward FY26 organic revenue growth of 1% to 2%.
  • Delivery of FY26 non-GAAP EPS of $2.10 to $2.15 at an effective non-GAAP tax rate of 27.5%.
  • The extent of organic margin expansion anticipated by management in 2026 and 2027.

Analysis

Bruker reported Q2-26 revenue of $838.5 million, up 5.2% year-over-year, and returned to organic growth of 2.8%. Organic growth was 3.4% excluding tariff refunds. Reported growth also reflected 1.5% growth from acquisitions and a favorable 0.9% foreign currency translation impact. For the first half, however, organic revenue decreased by 0.8% year-over-year, showing that the Q2 improvement followed a softer first-quarter backdrop.

BSI generated $767.3 million of Q2 revenue, up 4.7% year-over-year, while organic revenue increased 2.3%. The more significant demand indicator was BSI bookings, which increased 10% organically year-over-year, with book-to-bill above 1.0x. BEST grew faster, with revenue of $74.2 million up 11.9% and organic revenue up 8.9%, net of intercompany eliminations. Management identified semiconductor tools, energy research and biopharma as areas of strong order bookings, while US academic demand remained soft.

Profitability improved materially on the non-GAAP basis. Non-GAAP operating income rose to $118.5 million from $72.0 million, and non-GAAP operating margin improved to 14.1% from 9.0%. Non-GAAP diluted EPS increased to $0.49 from $0.32. GAAP operating loss was $(65.3) million and GAAP diluted loss per share was $(0.41), with second-quarter GAAP results including $134.9 million of non-cash goodwill impairment charges.

Bruker updated FY26 guidance for currency and tax only. It expects revenues of $3.54 to $3.57 billion, organic growth of 1% to 2%, and non-GAAP EPS of $2.10 to $2.15. The outlook incorporates an approximately 0.5% foreign currency translation revenue tailwind, previously 1.5%, and a currency headwind of approximately $0.10, or 5%, to non-GAAP EPS. The key reporting priorities are conversion of elevated BSI bookings into revenue, recovery in US academic demand, and continuation of the reported non-GAAP margin expansion.

Management, verbatim

We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year.

Frank H. Laukien, President and CEO

Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter.

Frank H. Laukien, President and CEO

In our academic and medical research business, US academic demand remained soft in Q2, while aca/gov bookings in Europe and China were up strongly.

Frank H. Laukien, President and CEO

Not in the filing

stated, not guessed
  • Q2-26 GAAP gross profit, gross margin, net income, cash flow from operations, free cash flow, cash balance, debt balance, dividends and share repurchases were not provided in the supplied filing text.
  • Q2-26 non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP net income, non-GAAP SG&A expense, non-GAAP interest and other income (expense), net, non-GAAP profit before income taxes and non-GAAP income tax rate were not provided in the supplied filing text.
  • FY26 guidance for gross margin and operating expenses was not provided in the supplied filing text.
  • Prior-quarter comparisons for reported metrics were not provided in the supplied filing text.
  • A previous outlook section was not provided, so comparison of actual results with prior guidance cannot be made.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

This is Bruker’s SEC Form 8-K (Item 2.02) with Q2 2026 results and an FY2026 outlook update.

Company-level read

Ticker impact

$BRKRBullishMedium confidence
Context

Bruker reported Q2 2026 revenue of $838.5M, non-GAAP EPS of $0.49, and updated FY2026 guidance for currency and tax only.

Expected impact

Likely modest positive bias for BRKR as traders price in improved non-GAAP EPS range ($2.10 to $2.15) and margin expansion, with upside capped by the guidance being currency/tax-only.

Evidence & confidence

The filing provides concrete quarterly results (revenue growth, non-GAAP EPS) and a specific FY2026 non-GAAP EPS range increase versus FY25, while stating the revenue and EPS outlook is updated only for currency and tax, reducing the probability of a major fundamental re-rating from this release alone.

Market effects

Scientific instruments and semiconductor tools demand signals (BSI bookings up 10% organically, BSI book-to-bill >1.0) may support sentiment across lab/analytical instrumentation peers.

No explicit regional macro shock; commentary highlights stronger aca/gov bookings in Europe and China versus soft US academic demand.

Currency and tax sensitivity is emphasized, which can matter for multinational instrumentation names with similar FX exposure.

Counterpoint

Because the company says FY2026 guidance is updated for currency and tax only, the market may overreact to the EPS range without a corresponding organic growth acceleration.

Key entities

  • Bruker Corporation

    Reported Q2 2026 financial results and updated FY2026 guidance for currency and tax only.

  • Bruker Scientific Instruments (BSI)

    Bookings up 10% organically YoY; BSI book-to-bill >1.0x; Q2 revenue $767.3M.

  • Bruker Energy & Supercon Technologies (BEST)

    Q2 revenue $74.2M, up 11.9% YoY with 8.9% organic growth net of intercompany eliminations.

Every BRKR earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$BRKRMed

Bruker Scientific Instruments BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection Bruker Energy & Supercon Technologies…

BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 As Reported As Recast Bruker Scientific Instruments ("BSI") BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") BSI NANO Bruker Energy & Supercon Technologies ("BEST") Corporate Total BSI Biosystems ("BIOS") BSI Microb

$BRKRHighAI 8/10

Bruker Corp (BRKR) Q3 2026 Earnings Call Highlights: Margin Expansion and Strong

Bruker Corp (BRKR) reported Q3 2026 with 0.7% organic revenue growth, but significant margin expansion, with non-GAAP gross margin up 120 bps to 51.3% and operating margin up 400 bps to 16.3%. Non-GAAP EPS grew 24% year-over-year to $0.56. Bookings trends remained positive, with BSI book-to-bill above 1 for five quarters. However, semiconductor metrology and NMR faced pushouts, and a $175 million goodwill impairment charge was recorded.

$BRKRHighAI 9/10

Why is Bruker stock surging today?

Bruker (BRKR) stock rose 14.2% after reporting Q3 2026 earnings of $0.56 per share, beating estimates by 33%, with revenue at $874M. Non-GAAP operating margin expanded 400 bps to 16.3%. Jefferies raised its price target to $70. Management reconfirmed full-year EPS guidance of $2.10–$2.15. The stock hit a 52-week high of $68.98.

$BRKRMed

Bruker (BRKR) Q3 2026 Earnings Call Transcript

Bruker (BRKR) reported Q3 2026 revenues of $874M, up 1.6% YoY, with non-GAAP EPS of $0.56, up 24%. CEO Frank Laukien highlighted growth in U.S. academic/government, China, and semiconductor metrology markets. The company expects revenue acceleration and margin expansion, driven by strong bookings trends and strategic investments in AI and organ-on-a-chip technologies.

$BRKRMed

Bruker Corporation Q3 2026 Earnings Call Summary

Bruker Corporation reported Q3 2026 earnings with 400 basis points year-over-year non-GAAP operating margin expansion. The BSI segment had a book-to-bill ratio over one for five quarters, and China BSI organic bookings grew over 20%. Management reconfirmed full-year 2026 organic revenue growth of 1% to 2% and non-GAAP EPS of $2.10 to $2.15. They expect double-digit EPS growth and at least 100 basis points of further operating margin expansion for fiscal year 2027.